Related Experiment Video
Updated: Aug 20, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Long-term disease-free acute promyelocytic leukemia patients really can be cured at molecular level
Abstract:
The characteristic t(15;17) translocation involving chromosomes 15 and 17 is specifically associated with both the common and the variant subtypes of acute promyelocytic leukemia (APL) (M3 according to FAB classification). At the molecular level, it fuses genes encoding PML on chromosome 15 and the nuclear retinoic acid receptor-alpha (RAR alpha) on chromosome 17. The subsequent expression of PML/RAR alpha fusion mRNA provides a potential molecular marker that can be detected in leukemic cells taken from patients with APL. Using PML and RARa sequence specific primers, reverse transcription-polymerase chain reaction (RT-PCR) assays have been developed for detection of PML/RAR alpha transcript in leukemic cells obtained from patients; these RT-PCR assays are more sensitive than conventional cytogenetic analysis.
Insights
Acute promyelocytic leukemia (APL) involves a specific chromosome translocation. Reverse transcription-polymerase chain reaction (RT-PCR) detects the resulting fusion gene, offering a sensitive diagnostic marker.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute promyelocytic leukemia (APL) is characterized by the t(15;17) translocation.
- This translocation fuses the PML gene on chromosome 15 with the retinoic acid receptor-alpha (RAR alpha) gene on chromosome 17.
- The resulting PML/RAR alpha fusion protein is a hallmark of APL.
Discussion:
- The PML/RAR alpha fusion mRNA serves as a specific molecular marker for APL.
- Reverse transcription-polymerase chain reaction (RT-PCR) assays can detect this fusion transcript in patient leukemic cells.
- RT-PCR offers enhanced sensitivity compared to conventional cytogenetic methods for APL diagnosis.
Key Insights:
- The t(15;17) translocation is a defining genetic event in APL.
- PML/RAR alpha fusion mRNA detection via RT-PCR is a sensitive diagnostic tool.
- Molecular detection aids in accurate APL subtyping and diagnosis.
Outlook:
- Further refinement of RT-PCR assays for APL detection.
- Integration of molecular diagnostics into routine APL clinical practice.
- Potential for monitoring minimal residual disease in APL patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...